JUN 19, 2019 09:27 AM PDT

Experimental Drug Encourages Bone Growth in Children with Dwarfism

WRITTEN BY: Nouran Amin

An experimental drug called vosoritide, alters certain proteins that block bone growth, which allowed the average annual growth of bone in a study of 35 children and teenagers with achondroplasia--a form of dwarfism.

"An increase in the annual growth rate alone may have a positive effect on some patients' quality of life. For other patients, now and in the future, our hope is that the altered bone growth throughout the body could ease such problems as sleep apnea, neurological and leg and back problems, and improve their quality of life," says Julie Hoover-Fong, M.D., Ph.D., associate professor and director of the Greenberg Center for Skeletal Dysplasias at the Johns Hopkins McKusick-Nathans Institute of Genetic Medicine. "Right now, the results of the study show an impact on growth, and this effect is sustained, at least over nearly four years in this trial. The potential long-term benefit will take more time to observe."

Results of the four-year study were reported in the New England Journal of Medicine.

About 20% of individuals living with achondroplasia will inherit the mutations. Besides dwarfism, other symptoms include developing sleep apnea, chronic ear infections, neurological problems, spinal stenosis and bowed legs. Many individuals will frequently require surgical treatments to relieve pain and other symptoms.

"About half of these children will need spinal or other surgery, and this can mean a lot of time away from school as the child recovers and rehabilitates after surgery, which can affect important social connections," says Ravi Savarirayan, M.B.B.S., M.D., clinical geneticist and group leader of skeletal biology and disease at Murdoch Children's Research Institute.

Learn more about achondroplasia:

There are currently no treatments that can reverse achondroplasia. However, vosoritide, a synthetic version of a natural protein present in humans called C-type natriuretic peptide, is designed to target the growth plates of bones. "This is the first therapeutic option that targets the molecular cause of the condition," says Hoover-Fong. “Importantly, none of the children experienced an anaphylactic reaction to the drug and none developed a low blood pressure problem that required medical intervention, which was a concern with this type of drug," says Hoover-Fong.

Source: Johns Hopkins University

 

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Possible Non-Antibiotic Strategy for Treating Bacterial Meningitis
Due to the increasing threat of antibiotic resistance, there is a dire need for new strategies against life threatening bacterial infections. Now, scientis...
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Potential of Statins to Treat Multiple Sclerosis
A widely used therapeutic statin, simvastatin, which is intended to treat cholesterol was found to be medically beneficial for patients with secondary prog...
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Repurposing Cancer Drug for Treating Brain Aneurysms
Brain aneurysms is a result of a bulging blood vessel due to a weakness in the blood vessel wall. When the blood passes through the weakened vessel walls, ...
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Miracle Drug for Rare Genetic Disease Causes Price Concerns
A newly approved “miracle drug” called Zolgensma will be used to treat children with spinal muscular atrophy, or SMA. Unfortunately, the therap...
JUL 18, 2019
Cell & Molecular Biology
JUL 18, 2019
Progress on a Potential Drug for Inflammatory Disease
A team of researchers is trying to develop a treatment for chronic inflammatory disorders by inhibiting a complex called the NLRP3 inflammasome....
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Effective Treatment for Ulveal Melanoma
Uveal melanoma is a rare and aggressive type of melanoma that targets the eye and affects an estimated 2,500 people in the United States annually. Nearly h...
Loading Comments...